Your session is about to expire
← Back to Search
Telmisartan for Alzheimer's Disease (SARTAN-AD Trial)
SARTAN-AD Trial Summary
This trial will test whether an ARB can slow brain atrophy in patients with Alzheimer's Disease compared to an ACEI.
- Alzheimer's Disease
SARTAN-AD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 4 trial • 33 Patients • NCT02079805SARTAN-AD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a type of Alzheimer's disease that runs in families and is inherited from one generation to another.You cannot tolerate or have any medical reasons to avoid taking the study medications.You have experienced angioedema in the past.You are currently taking or have taken a medication called angiotensin receptor blocker within the past year.Your mental state will be assessed using a test, and if your score falls between 16 and 27, you may be excluded from the trial.You have abnormal blood vessels in your brain, regardless of their size or number.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Perindopril
- Group 2: Telmisartan
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Has Telmisartan been sanctioned by the Food and Drug Administration?
"Telmisartan's safety has been demonstrated in preliminary testing, so it can be assigned a score of 2 on our risk scale. However, there is not yet any clinical data that demonstrates its efficacy."
What conditions are typically addressed with Telmisartan medication?
"Telmisartan is a widely used treatment for high cardiovascular risk patients, but it can be beneficial in other scenarios like cerebrovascular accident prevention and those who are unable to take ACE inhibitors."
Are there numerous healthcare centers in North America offering this trial?
"This trial is recruiting in 10 centres total, some of which include UBC Hospital in Lethbridge, University of Lethbridge in Hamilton and Hamilton General Hospital in Toronto."
Are there still vacancies for participants in this experiment?
"Affirmative, clinicaltrials.gov indicates that this research study is currently enrolling patients. This trial was initially declared on March 1st 2014 and updated as recently as May 3rd 2022. To complete the investigation, 150 participants across 10 different locations must be recruited."
How many participants are participating in this medical research?
"150 qualified individuals must partake in this trial, which is being administered at UBC Hospital in Lethbridge and University of Lethbridge in Hamilton. In order to be accepted as a participant, applicants must meet the given criteria."
Have there been any other investigations involving Telmisartan?
"Telmisartan was first investigated at Uchiyama Clinic in 2012 and there have since been 228 completed studies. At the current moment, 15 trials are gathering participants primarily out of Lethbridge, Alberta."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger